Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1996 3
1997 1
1998 1
2002 1
2003 1
2004 3
2005 4
2006 4
2007 6
2008 4
2009 9
2010 4
2011 6
2012 12
2013 17
2014 12
2015 21
2016 35
2017 45
2018 39
2019 48
2020 64
Text availability
Article attribute
Article type
Publication date

Search Results

310 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Delivery technologies for cancer immunotherapy.
Riley RS, June CH, Langer R, Mitchell MJ. Riley RS, et al. Nat Rev Drug Discov. 2019 Mar;18(3):175-196. doi: 10.1038/s41573-018-0006-z. Nat Rev Drug Discov. 2019. PMID: 30622344 Free PMC article. Review.
Immunotherapy has become a powerful clinical strategy for treating cancer. ...Here, we discuss these research advances, as well as the opportunities and challenges for integrating delivery technologies into cancer immunotherapy, and we cr
Immunotherapy has become a powerful clinical strategy for treating cancer. ...Here, we discuss these research advances,
Integrative strategy for improving cancer immunotherapy.
Cao X. Cao X. J Mol Med (Berl). 2016 May;94(5):485-7. doi: 10.1007/s00109-016-1424-1. J Mol Med (Berl). 2016. PMID: 27114349 No abstract available.
Prospects for combining targeted and conventional cancer therapy with immunotherapy.
Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, Mueller B, Quaratino S, Sabatos-Peyton C, Petruzzelli L, Engelman JA, Dranoff G. Gotwals P, et al. Nat Rev Cancer. 2017 May;17(5):286-301. doi: 10.1038/nrc.2017.17. Epub 2017 Mar 24. Nat Rev Cancer. 2017. PMID: 28338065 Review.
Over the past 25 years, research in cancer therapeutics has largely focused on two distinct lines of enquiry. ...The integration of these potentially complementary research fields provides new opportunities to improve cancer treatments. ...
Over the past 25 years, research in cancer therapeutics has largely focused on two distinct lines of enquiry. ...The integration
NK cells and exercise: implications for cancer immunotherapy and survivorship.
Bigley AB, Simpson RJ. Bigley AB, et al. Discov Med. 2015 Jun;19(107):433-45. Discov Med. 2015. PMID: 26175401 Free article. Review.
Tumor infiltration by NK-cells is associated with prolonged survival in cancer patients and high NK-cell cytotoxicity has been linked to decreased cancer risk. ...Thus, we suggest that either acute exercise or in vitro expansion of NKG2C+/NKG2A- NK-cells (as seen in …
Tumor infiltration by NK-cells is associated with prolonged survival in cancer patients and high NK-cell cytotoxicity has been linked …
The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer.
Ko EC, Raben D, Formenti SC. Ko EC, et al. Clin Cancer Res. 2018 Dec 1;24(23):5792-5806. doi: 10.1158/1078-0432.CCR-17-3620. Epub 2018 Jun 26. Clin Cancer Res. 2018. PMID: 29945993 Free article. Review.
Improvements have been made in the outcomes of patients with NSCLC due to advancements in radiotherapy (RT) techniques, the use of concurrent chemotherapy with RT, and the emergence of immunotherapy as first- and second-line treatment in the metastatic setting. ...H
Improvements have been made in the outcomes of patients with NSCLC due to advancements in radiotherapy (RT) techniques, the use of co
Anti-GD2 immunotherapy for neuroblastoma.
Sait S, Modak S. Sait S, et al. Expert Rev Anticancer Ther. 2017 Oct;17(10):889-904. doi: 10.1080/14737140.2017.1364995. Epub 2017 Aug 14. Expert Rev Anticancer Ther. 2017. PMID: 28780888 Free PMC article. Review.
Current therapeutic approaches for high-risk neuroblastoma (HR-NB) include high-dose chemotherapy, surgery and radiotherapy; interventions that are associated with long and short-term toxicities. Effective immunotherapy holds particular promise for improving surviva …
Current therapeutic approaches for high-risk neuroblastoma (HR-NB) include high-dose chemotherapy, surgery and radiotherapy; interventions t …
Advances in cancer immunotherapy 2019 - latest trends.
Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M. Kruger S, et al. J Exp Clin Cancer Res. 2019 Jun 19;38(1):268. doi: 10.1186/s13046-019-1266-0. J Exp Clin Cancer Res. 2019. PMID: 31217020 Free PMC article. Review.
Immunotherapy has become an established pillar of cancer treatment improving the prognosis of many patients with a broad variety of hematological and solid malignancies. ...Different strategies to translate the striking success of CAR T cells in B cell
Immunotherapy has become an established pillar of cancer treatment improving the prognosis of many patients with a broa
Hodgkin lymphoma: A review and update on recent progress.
Shanbhag S, Ambinder RF. Shanbhag S, et al. CA Cancer J Clin. 2018 Mar;68(2):116-132. doi: 10.3322/caac.21438. Epub 2017 Dec 1. CA Cancer J Clin. 2018. PMID: 29194581 Free PMC article. Review.
Alternate donor sources and reduced-intensity conditioning have made allogeneic hematopoietic stem cell transplantation a viable option for more patients. Future research will look to integrate novel strategies into earlier lines of therapy to improve the HL …
Alternate donor sources and reduced-intensity conditioning have made allogeneic hematopoietic stem cell transplantation a viable option for …
Treatment strategies for endometrial cancer: current practice and perspective.
Lee YC, Lheureux S, Oza AM. Lee YC, et al. Curr Opin Obstet Gynecol. 2017 Feb;29(1):47-58. doi: 10.1097/GCO.0000000000000338. Curr Opin Obstet Gynecol. 2017. PMID: 27941361 Review.
Optimal adjuvant treatment strategy in high-risk endometrial cancer remains to be defined with recognition of treatment-related toxicity. ...There is an urgent need for scientifically validated therapy with predictive biomarkers. SUMMARY: Our understanding of endome …
Optimal adjuvant treatment strategy in high-risk endometrial cancer remains to be defined with recognition of treatment-relate …
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T. Mariathasan S, et al. Nature. 2018 Feb 22;554(7693):544-548. doi: 10.1038/nature25501. Epub 2018 Feb 14. Nature. 2018. PMID: 29443960 Free PMC article.
Therapeutic antibodies that block the programmed death-1 (PD-1)-programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients with various cancers, including metastatic urothelial cancer. However, these responses only occur in a subse …
Therapeutic antibodies that block the programmed death-1 (PD-1)-programmed death-ligand 1 (PD-L1) pathway can induce robust and durable resp …
310 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback